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Abstract
Purpose Majority of pediatric cancer patients are treated with
chemotherapy using Venous Access Ports (VAP). However,
after surgical removal of the VAP prominent scars often re-
main and standard care is lacking.
Methods Patients (N = 20) who were willing to participate
were included prior to surgical removal of their VAP. All pa-
tients were off therapy at time of VAP removal. Patients had
the option to either choose from Dermatix®, meridian color
therapy (MCT), or no additional treatment (NAT). Assessment
of scars was done prior to and 3, 6, and 12 months after
surgical VAP removal using Patient and Observer Scar
Assessment Scales (POSAS) questionnaires. To identify
whether Dermatix® or MCT is associated with better scar
healing than without additional treatment, Mann-Whitney U
tests were used.
Results After 12 months of follow-up, both patients and der-
matologists noted VAP scars had healed better after MCT
compared to those without treatment (P = 0.010 for both
POSAS patient and POSAS observer). No significant
differences were observed between VAP scars after
Dermatix® use and those with no treatment.
Conclusions Scar healing after MCT significantly improved,
whereas Dermatix® treatment showed no significant differ-
ences compared to NAT. To translate this to daily care, a larger
prospective study is needed to validate these findings.
Keywords VAP . Scar healing . Pediatric oncology
Introduction
Majority of pediatric cancer patients are treated with chemo-
therapy. For optimal administration of long-term intravenous
treatment, implementation of venous access ports (VAP) is
part of the standard care. In the University Medical Center
Groningen, VAP catheters are usually positioned in the sub-
clavian or external jugular vein, whereas the VAP reservoir is
positioned below the clavicle. Unfortunately, after removal of
the VAP prominent scars often remain, which can be debili-
tating for patients. A recent study showed that 33% of the
adult childhood cancer survivors reported treatment-related
scarring, associated with body imagine disturbance, emotional
distress, and reduced quality of life. Moreover, the proportion
of patients that reported head/neck scarring was highest
among survivors between the age of 10 and 14 years old,
which is a critical time for developing self-esteem. [1]
Another study reported that 15% of the psychological prob-
lems in survivors of childhood cancer resulted from scar for-
mation. [2]
Information regarding standardized care of VAP scars is
not available. In daily practice, treatment options are used to
optimize healing of the VAP scar, including meridian color
therapy (MCT), and silicone gel (Dermatix®). MCT is a treat-
ment based on the reflective zones of the connective tissue, the
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anthroposophical color system, and acupuncture. It restores
blockages in energy flows (meridians) by adding color fre-
quencies with silk patches dyed with natural pigments of
plants. [3] Despite lack of scientific evidence, patients report-
ed positive results that suggest potential benefits for VAP scar
treatment. Likewise, dermatologists experienced positive re-
sults with Dermatix® in scar treatment. Dermatix® can be
applied easily, and the mechanism is based on recovering skin
moisture, restoring skin structures and stimulating collagen
production. [4]
Due to lack of evidence-based standardized care for VAP
scars, the aim was to assess scar healing in patients who were
willing to share their healing process. Patients were enabled to
decide themselves between treatment with silicone gel
(Dermatix®), meridian color therapy (MCT), or no additional
treatment (NAT).
Methods
Twenty pediatric cancer patients with a history of chemother-
apy treatment who were willing to share their healing process
were followed prior to and after surgical VAP removal be-
tween March 2014 and March 2016. Patients had a median
age of 7.65 years (range 1.51–15.13), and 65% (N = 13/20) of
the patients were female. All patients were off therapy at time
of VAP removal and no local complications (e.g., VAPwound
infection or hypertrophic scar formation) were observed.
Patients had the option to choose Dermatix®, MCT, or NAT
after VAP removal. Patients who opted for Dermatix® were
advised to start with daily application after the wound had
healed superficially. When opting for MCT, patients were
counseled by a MCT therapist beforehand and had to apply
colored silk bandages at determined meridian points of the
skin. Both MCT and Dermatix® were applied at home for at
least 6 months. No adjustments were made in addition to the
standardized protocol for surgical VAP removal.
Scar healing was assessed prior to and 3, 6, and 12 months
after VAP removal using the Patient and Observer Scar
Assessment Scales (POSAS). [5] The POSAS scale is divided
into two parts: a patient scale and an observer scale. Scales
numerically score six items on a measure from one to ten,
where a lower score represented better scar recovery. Parents
filled out the POSAS questionnaire if patients were <8 years.
Additionally, photographs of the VAP scars were taken, using
a Canon camera (Eos 600D DS126311, Macro lens EF-S
60 mm). Two independent dermatologists assessed the scars
retrospectively without any knowledge of the scar treatment.
Dermatologists were trained to consistently use the POSAS
scale. If large intervariability was observed between dermatol-
ogists, re-assessment of that particular scar was done.
To identify whether Dermatix® or MCT was associated
with better scar healing and to assess whether scars improved
within treatment groups after 12months compared to 3months,
Mann-WhitneyU tests were used. Statistical analysis was done
using the SPSS statistical software (IBM SPSS Statistics 22)
and the figure was generated in R (Version 0.99.484).
Intervariability between the two dermatologists was determined
using the reliability analysis (Cronbach’s alpha).
Results
Twenty-one scars were analyzed of which one patient had two
scars. Eight scars were treated with Dermatix®, seven with
MCT, and six withNAT.No statistical differenceswere observed
for gender, duration of the VAP in situ, or age between the
treatment groups. Scar assessment showed no intervariability
between dermatologists (Cronbach’s alpha = 0.933).
Prior to removal of the VAP, the POSAS observer scale
showed higher scores for patients who intended to start
MCT compared to patients who chose NAT (P = 0.007).
Strikingly, patients who chose MCT treatment assessed their
former scar superior compared to the control group, although
this was not significantly (P = 0.086). POSAS observer scores
showed no differences between patients who chose
Dermatix® compared to patients with NAT (P = 0.826).
Likewise, assessment done by patients using Dermatix®
showed no differences compared to patients without treatment
(P = 0.061). POSAS scores of patients and dermatologists are
shown in Fig. 1.
After VAP removal, scar evaluations of patients and ob-
servers showed lower POSAS scores for MCT compared to
NATat 6 and 12months (P = 0.017;P = 0.042 at 6months and
P = 0.010; P = 0.010 at 12 months for, respectively, patients
and observers). Similarly, scars treated with Dermatix®
showed lower POSAS patient scores compared to NAT at
3 months (P = 0.022), but this was not confirmed by derma-
tologist’ assessment (P = 0.116) and did not last after
12 months. Despite superior scar healing for patients using
MCTcompared to patients with NAT, no significant improve-
ment was seen between T3 and T12 within patients using
MCT. Also, no improvements over time were seen after
Dermatix® application. Fig. 2 shows three examples of scar
healing, each representing a different treatment option.
Discussion
Chemotherapy is still the mainstay of treatment for pediatric
cancer patients, and to optimize long-term intravenous admin-
istration VAPs are frequently implemented. Although great
progress has been achieved in cancer-treatment outcome, little
focus has been directed to scar-related consequences of VAP
treatment that may negatively affect psychological function-
ing. This manuscript aimed to compare two potential
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treatments to optimize VAP scar healing in pediatric patients
compared to NAT.
The prime discovery in this study was improved scar
healing after removal of the VAP in patients that used MCT
compared to patients with NAT predicated upon lower
POSAS scores. No significant improvement in scar healing
was observed after Dermatix® application. The feature that
makes this observation strong was scar assessment performed
by both patients and dermatologists.
Since patients who chose MCT, assessed their scars more
positively before and after VAP removal; this could imply that
patients who chose MCT had a more optimistic perception.
However, dermatologist did not confirm this finding. They did
agree with the improvement of the scars after 6 and 12months
compared to the scars with NAT. Although scar healing after
MCTwas significantly better compared to NAT, no improve-
ment was seen after 12 months compared to 3 months. This
could suggest that the follow-up time was too short to attain
optimal scar healing in our patient group.
To translate these outcomes to daily care, a larger study is
needed to confirm these findings. More patients should be
included, and follow-up time should be increased to ensure
Fig. 1 Scar assessment prior to
and at 3, 6, and 12 months after
surgical VAP removal using the
POSAS patient scale (upper) and
POSAS observer scale (lower).
Patients without additional
treatment are shown in light gray,
patients using Dermatix® in
white and patients using MCT are
shown in dark gray. Horizontal
bars indicate median scores and a
lower score represents better scar
recovery. Asterisks (*) indicate
significant differences (P < 0.05)
compared to natural scar recovery
Fig. 2 Scar evaluations at 3 and
12 months after VAP removal.
Scar recovery at 3 and 12 months
after removal of the VAP is shown
for three patients, each
representing a different treatment
option; natural scar healing,
Dermatix®, and MCT. All
patients agreed upon using their
scar photographs
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maximal scar-recovery. During time of follow-up, patients
were asked to use therapy for at least 6 months. However,
no certainty was given according to compliance to therapy,
which may have affected our results. Therefore, future studies
should thoroughly try to monitor compliance to therapy. Also,
a standardized surgery procedure concerning suture material
and techniques needs to be incorporated as this may affect scar
healing. Moreover, it would be interesting to determine
whether inferior scar healing affects the quality of life and
whether better scar recovery improves the quality of life. In
conclusion, MCT showed more promising results and could
be considered for optimization of the scar healing after surgi-
cal VAP removal in pediatric cancer patients.
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